Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Alternative Behandlungsoptionen beim Basalzellkarzinom am Auge

Alternative treatment options for periorbital basal cell carcinoma



Neuste Entwicklungen, aber auch ältere Verfahren bieten, soweit die mikrographisch kontrollierte Chirurgie nicht zum Einsatz kommen kann, alternative Therapieverfahren beim Basalzellkarzinom an.


Dargestellt werden alternative Therapieoptionen bei periokulären Basalzellkarzinomen.


Es erfolgen eine Literaturrecherche sowie eine strukturierte Darstellung und Bewertung der Ergebnisse.


Die mikrographisch kontrollierte Chirurgie ist der Goldstandard der Therapie der Basalzellkarzinome. Wenn die Chirurgie aus verschiedensten Gründen nicht erfolgen kann, werden andere Verfahren benötigt. Die alternativen Behandlungsoptionen beim Basalzellkarzinom lassen sich in 3 Gruppen unterteilen: Behandlungsoptionen für lokal fortgeschrittene Basalzellkarzinome bzw. für metastasierte Basalzellkarzinome, topische Verfahren für kleine und oberflächliche Basalkarzinome sowie prophylaktische Maßnahmen. Während die Bestrahlung und die Systemtherapie bei lokal fortgeschrittenen Basalzellkarzinomen Sinn ergeben und im Tumorboard besprochen werden, können kleine und oberflächliche Befunde topisch behandelt werden. Eine Prophylaxe kann bei einer vorherigen Basalzellkarzinomhistorie durchgeführt werden. Gerade Systemtherapiekombinationen, aber auch ein neoadjuvanter oder adjuvanter Ansatz vor oder nach der Chirurgie sind weitere Erfolg versprechende Möglichkeiten, die beim lokal fortgeschrittenen Basalzellkarzinom den Behandlungsstandard weiter verbessern können.


Alternative Behandlungsoptionen beim periokulären Basalzellkarzinom existieren. Allerdings ist deren Einsatz ausschließlich indiziert, wenn die mikroskopisch kontrollierte Exzision mit anschließender okuloplastischer Rekonstruktion nicht möglich ist. Nahezu zwingend nach den nationalen Leitlinien ist eine vorherige Vorstellung in einem geeigneten Tumorboard.



Latest developments as well as established procedures offer alternative treatment approaches to basal cell carcinoma (BCC) when micrographically controlled surgical removal is not a valid option.


Alternative treatment options for periorbital BCC are presented.


A literature search was carried out and a structured display and analysis of the results are given.


Micrographically controlled surgical removal represents the gold standard in treatment of BCC. When for various reasons surgical removal is not a valid option, other procedures are required. The alternative treatment options can be divided into three main groups: treatment options for locally advanced or metastasized BCC, topical approaches for small and superficial BCC and prophylactic measures. While radiotherapy and systemic therapy are suitable for locally advanced BCC and are discussed in a tumor board, small and superficial BCC can be treated by topical medication. In cases of a previous BCC history, a prophylactic treatment can be considered. Combinations of systemic treatment and also neoadjuvant or adjuvant approaches before and after surgery are promising options for a successful outcome, which can further improve the standard treatment for locally advanced BCC.


Alternative treatment options for periocular BCC are available; however, the use is only indicated when microscopically controlled excision with subsequent oculoplastic reconstruction is not possible. According to the national guidelines a prior presentation to a suitable tumor board is practically compulsory.

This is a preview of subscription content, log in to check access.

Abb. 1
Abb. 2


  1. 1.

    Lang BM, Balermpas P, Bauer A, Blum A, Brolsch GF, Dirschka T et al (2019) S2k-Leitlinie Basalzellkarzinom der Haut – Teil 2: Therapie, Pravention und Nachsorge. J Dtsch Dermatol Ges 17(2):214–231

  2. 2.

    Lang BM, Balermpas P, Bauer A, Blum A, Brolsch GF, Dirschka T et al (2019) S2k-Leitlinie Basalzellkarzinom der Haut – Teil 1: Epidemiologie, Genetik und Diagnostik. J Dtsch Dermatol Ges 17(1):94–104

  3. 3.

    Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB et al (2019) Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer 118:10–34

  4. 4.

    Rishi A, Huang HS, O’Sullivan B, Goldstein DP, Lu L, Ringash J et al (2017) Outcome following radiotherapy for head and neck basal cell carcinoma with “aggressive” features. Oral Oncol 72:157–164

  5. 5.

    Duinkerken CW, Lohuis P, Crijns MB, Navran A, Haas RLM, Hamming-Vrieze O et al (2017) Orthovoltage X‑rays for postoperative treatment of resected basal cell carcinoma in the head and neck area. J Cutan Med Surg 21(3):243–249

  6. 6.

    Duinkerken CW, Lohuis PJ, Heemsbergen WD, Zupan-Kajcovski B, Navran A, Hamming-Vrieze O et al (2016) Orthovoltage for basal cell carcinoma of the head and neck: excellent local control and low toxicity profile. Laryngoscope 126(8):1796–1802

  7. 7.

    Ballester-Sanchez R, Pons-Llanas O, Candela-Juan C, Celada-Alvarez FJ, Barker CA, Tormo-Mico A et al (2016) Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses. J Contemp Brachytherapy 8(1):48–55

  8. 8.

    Ballester-Sanchez R, Pons-Llanas O, Candela-Juan C, Celada-Alvarez FJ, de Unamuno-Bustos B, Llavador-Ros M et al (2015) Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma. J Contemp Brachytherapy 7(3):231–238

  9. 9.

    Delishaj D, Rembielak A, Manfredi B, Ursino S, Pasqualetti F, Laliscia C et al (2016) Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature. J Contemp Brachytherapy 8(6):533–540

  10. 10.

    Piccinno R, Benardon S, Gaiani FM, Rozza M, Caccialanza M (2017) Dermatologic radiotherapy in the treatment of extensive basal cell carcinomas: a retrospective study. J Dermatolog Treat 28(5):426–430

  11. 11.

    Delishaj D, Laliscia C, Manfredi B, Ursino S, Pasqualetti F, Lombardo E et al (2015) Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: a retrospective case series. J Contemp Brachytherapy 7(6):437–444

  12. 12.

    Valeriani M, Nicosia L, Agolli L, Reverberi C, Galvagno E et al (2017) Mono- and Bi-weekly hypofractionated radiation therapy for the treatment of epithelial skin cancer in very elderly patients. Anticancer Res 37(2:825–830

  13. 13.

    Rowe DE, Carroll RJ, Day CL Jr. (1989) Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 15(3):315–328

  14. 14.

    Wiegell SR, Skodt V, Wulf HC (2014) Daylight-mediated photodynamic therapy of basal cell carcinomas—an explorative study. J Eur Acad Dermatol Venereol 28(2):169–175

  15. 15.

    Lovett RD, Perez CA, Shapiro SJ, Garcia DM (1990) External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys 19(2):235–242

  16. 16.

    Griep C, Davelaar J, Scholten AN, Chin A, Leer JW (1995) Electron beam therapy is not inferior to superficial x‑ray therapy in the treatment of skin carcinoma. Int J Radiat Oncol Biol Phys 32(5):1347–1350

  17. 17.

    Pampena R, Palmieri T, Kyrgidis A, Ramundo D, Iotti C, Lallas A et al (2016) Orthovoltage radiotherapy for nonmelanoma skin cancer (NMSC): comparison between 2 different schedules. J Am Acad Dermatol 74(2):341–347

  18. 18.

    Avril MF, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E et al (1997) Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 76(1):100–106

  19. 19.

    Hauschild A, Breuninger H, Kaufmann R, Kortmann RD, Klein M, Werner J et al (2013) Brief S2k guidelines—basal cell carcinoma of the skin. J Dtsch Dermatol Ges 11(Suppl 3:10–5):1–6

  20. 20.

    Rio E, Bardet E, Ferron C, Peuvrel P, Supiot S, Campion L et al (2005) Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases. Int J Radiat Oncol Biol Phys 63(3):753–757

  21. 21.

    Berking C, Hauschild A, Kolbl O, Mast G, Gutzmer R (2014) Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int 111(22):389–395

  22. 22.

    Cho M, Gordon L, Rembielak A, Woo TC (2014) Utility of radiotherapy for treatment of basal cell carcinoma: a review. Br J Dermatol 171(5):968–973

  23. 23.

    Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122

  24. 24.

    Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A et al (2010) Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76(3 Suppl):S10–S19

  25. 25.

    McKeown SR, Hatfield P, Prestwich RJ, Shaffer RE, Taylor RE (2015) Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol 88(1056):20150405

  26. 26.

    Taylor RE, Hatfield P, McKeown SR, Prestwich RJ, Shaffer R (2015) Radiotherapy for benign disease: current evidence, benefits and risks. Clin Oncol 27(8):433–435

  27. 27.

    Bale AE, Yu KP (2001) The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 10(7):757–762

  28. 28.

    Teh MT, Blaydon D, Chaplin T, Foot NJ, Skoulakis S, Raghavan M et al (2005) Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 65(19):8597–8603

  29. 29.

    Kakkassery V, Loeffler KU, Sand M, Koch KR, Lentzsch AM, Nick AC et al (2017) Current diagnostics and therapy recommendations for ocular basal cell carcinoma. Ophthalmologe 114(3):224–236

  30. 30.

    Kakkassery V, Heindl LM (2017) SOP—standarized procedures in diagnostics and therapies of periocular basal cell carcinoma. Klin Monbl Augenheilkd.

  31. 31.

    Rokohl AC, Loser H, Mor JM, Loreck N, Koch KR, Heindl LM (2019) Young male patient with unusual space-occupying lesion of the lower eyelid. Ophthalmologe.

  32. 32.

    Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171–2179

  33. 33.

    Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S et al (2015) Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 72(6):1021–1026.e8

  34. 34.

    Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K et al (2012) Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366(23):2180–2188

  35. 35.

    Basset-Seguin N, Hauschild A, Kunstfeld R, Grob J, Dreno B, Mortier L et al (2017) Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 86:334–348

  36. 36.

    Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P et al (2015) Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 16(6):716–728

  37. 37.

    Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P et al (2016) The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 75(1):113–125.e5

  38. 38.

    Gill HS, Moscato EE, Chang AL, Soon S, Silkiss RZ (2013) Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol 131(12):1591–1594

  39. 39.

    Demirci H, Worden F, Nelson CC, Elner VM, Kahana A (2015) Efficacy of vismodegib (erivedge) for basal cell carcinoma involving the orbit and periocular area. Ophthal Plast Reconstr Surg 31(6):463–466

  40. 40.

    Papastefanou VP, Rene C (2015) Secondary resistance to vismodegib after initial successful treatment of extensive recurrent periocular basal cell carcinoma with orbital invasion. Ophthal Plast Reconstr Surg.

  41. 41.

    Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN et al (2015) Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol 160(2):220–227.e2

  42. 42.

    Lauterbach B, Kakkassery V, Debus D, Heindl LM, Schultz ES (2019) Advanced periocular basal cell carcinoma—a therapeutic challenge. Ophthalmologe 116(3):273–277

  43. 43.

    Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I et al (2014) An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol 71(5):904–9011.e1

  44. 44.

    Sand M, Bechara FG, Gambichler T, Sand D, Friedlander MR, Bromba M et al (2016) Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study. Ann Oncol 27(2):332–338

  45. 45.

    Boeckmann L, Martens MC, Kakkassery V, Heindl LM, Emmert S (2019) Molecular genetic investigations as the basis for targeted treatment of basal cell carcinoma of the eye. Ophthalmologe.

  46. 46.

    Eiger-Moscovich M, Reich E, Tauber G, Berliner O, Priel A, Simon BG et al (2019) Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma. Am J Ophthalmol.

  47. 47.

    Mathis J, Doerr T, Lin E, Ibrahim SF (2019) Oral hedgehog pathway inhibition as a means for ocular salvage in locally advanced Intraorbital basal cell carcinoma. Dermatol Surg 45(1):17–25

  48. 48.

    Sagiv O, Ding S, Ferrarotto R, Glisson B, Altan M, Johnson F et al (2019) Impact of food and drug administration approval of vismodegib on prevalence of orbital exenteration as a necessary surgical treatment for locally advanced periocular basal cell carcinoma. Ophthalmic Plast Reconstr Surg 35(4):350–353

  49. 49.

    Hogarty DT, Dewhurst NG, Burt B (2018) Vismodegib and orbital excision for treating locally advanced basal cell carcinoma. Int Med Case Rep J 11:177–179

  50. 50.

    Khalid B, Mukherjee S, Ibrahimi S, Cannon T, Gilles E, Moreau A et al (2018) Switching the smoothened inhibitor may have benefit in advanced basal cell carcinoma. Am J Ther 25(3):e394–e6

  51. 51.

    Gunduz K, Yanik O (2015) Myths in the diagnosis and management of orbital tumors. Middle East Afr J Ophthalmol 22(4):415–420

  52. 52.

    Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833

  53. 53.

    Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18(1):31–41

  54. 54.

    Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133

  55. 55.

    Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA‑4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384

  56. 56.

    Sabbatino F, Marra A, Liguori L, Scognamiglio G, Fusciello C, Botti G et al (2018) Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. J Immunother Cancer 6(1):126

  57. 57.

    Fischer S, Ali HO, Jochum W, Kluckert T, Flatz L, Siano M (2018) Anti-PD‑1 therapy leads to near-complete remission in a patient with metastatic basal cell carcinoma. Oncol Res Treat 41(6):391–394

  58. 58.

    Cannon JGD, Russell JS, Kim J, Chang ALS (2018) A case of metastatic basal cell carcinoma treated with continuous PD‑1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. JAAD Case Rep 4(3):248–250

  59. 59.

    Lipson EJ, Lilo MT, Ogurtsova A, Esandrio J, Xu H, Brothers P et al (2017) Basal cell carcinoma: PD-L1/PD‑1 checkpoint expression and tumor regression after PD‑1 blockade. J Immunother Cancer 5:23

  60. 60.

    Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I et al (2016) Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer 4:70

  61. 61.

    Reinhold U (2011) Electrochemotherapy for primary skin cancer and skin metastasis related to other malignancies. Anticancer Drugs 22(8):711–718

  62. 62.

    Kreuter A, van Eijk T, Lehmann P, Fischer M, Horn T, Assaf C et al (2015) Electrochemotherapy in advanced skin tumors and cutaneous metastases—a retrospective multicenter analysis. J Dtsch Dermatol Ges 13(4):308–315

  63. 63.

    Bourke MG, Salwa SP, Sadadcharam M, Whelan MC, Forde PF, Larkin JO et al (2017) Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: ten-year audit of single centre experience. Breast Cancer Res Treat 161(2):289–297

  64. 64.

    Campana LG, Testori A, Curatolo P, Quaglino P, Mocellin S, Framarini M et al (2016) Treatment efficacy with electrochemotherapy: a multi-institutional prospective observational study on 376 patients with superficial tumors. Eur J Surg Oncol 42(12):1914–1923

  65. 65.

    Kis E, Baltas E, Kinyo A, Varga E, Nagy N, Gyulai R et al (2012) Successful treatment of multiple basaliomas with bleomycin-based electrochemotherapy: a case series of three patients with Gorlin-Goltz syndrome. Acta Derm Venereol 92(6):648–651

  66. 66.

    Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M (2004) Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50(5):722–733

  67. 67.

    Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS et al (2014) Surgical excision versus imiquimod 5 % cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 15(1):96–105

  68. 68.

    Williams HC, Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W et al (2017) Surgery versus 5 % Imiquimod for nodular and superficial basal cell carcinoma: 5‑year results of the SINS randomized controlled trial. J Invest Dermatol 137(3):614–619

  69. 69.

    Love WE, Bernhard JD, Bordeaux JS (2009) Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 145(12):1431–1438

  70. 70.

    Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P (1986) Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol 37(1):33–34

  71. 71.

    Ramsay JR, Suhrbier A, Aylward JH, Ogbourne S, Cozzi SJ, Poulsen MG et al (2011) The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol 164(3):633–636

  72. 72.

    Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM (2010) PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol 51(2):99–105

  73. 73.

    Brinkhuizen T, Frencken KJ, Nelemans PJ, Hoff ML, Kelleners-Smeets NW, Zur Hausen A et al (2016) The effect of topical diclofenac 3 % and calcitriol 3 mug/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. J Am Acad Dermatol 75(1):126–134

  74. 74.

    Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA et al (2015) A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 373(17):1618–1626

  75. 75.

    Park SM, Li T, Wu S, Li WQ, Weinstock M, Qureshi AA et al (2017) Niacin intake and risk of skin cancer in US women and men. Int J Cancer 140(9):2023–2031

  76. 76.

    Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB et al (2012) Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer 118(8):2128–2137

Download references


Die Arbeit wurde zum Teil unterstützt durch OnkoTher‑H, EU, ESF/14-BM-A55-0001/18, der Damp Stiftung 2017-05 und der Dermatologischen Gesellschaft Mecklenburg-Vorpommern (S. E.).

Author information

Correspondence to PD Dr. med. Vinodh Kakkassery.

Ethics declarations


V. Kakkassery hat Vortragshonorare von der Firma Roche, Bayer, Allergan und Novartis sowie Beratungshonorare von der Firma Roche und Novartis erhalten. S. Emmert, I.A. Adamietz, G. Kovács, A.M. Jünemann, C. Otte, M. Zimbelmann, A. Brosig, S. Grisanti und L.M. Heindl geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kakkassery, V., Emmert, S., Adamietz, I.A. et al. Alternative Behandlungsoptionen beim Basalzellkarzinom am Auge. Ophthalmologe 117, 113–123 (2020).

Download citation


  • Bestrahlung
  • Tumorboard
  • Hedgehog-Inhibitoren
  • Topische Therapie
  • Prophylaxe


  • Irradiation
  • Tumor board
  • Hedgehog protein inhibitors
  • Topical treatment
  • Prophylaxis